Renal Cancer - Results from #5820

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial March 13, 2016

Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients March 11, 2016

Clear Cell Renal Cell Carcinoma: Associations Between CT Features and Patient Survival March 11, 2016

The importance of surgical margins in renal cell and urothelial carcinomas March 11, 2016

Surgical Management of Renal Cell Cancer Liver Metastases March 11, 2016

[WHO classification 2016 and first S3 guidelines on renal cell cancer : What is important for the practice?] March 8, 2016

Identification of biological targets of therapeutic intervention for clear cell renal cell carcinoma based on bioinformatics approach March 8, 2016

Sequential unusual site metastases in renal cell cancer: Saga of repeated tumor implantation and prolonged survival without systemic therapy March 7, 2016

Metformin and the risk of renal cell carcinoma: a case-control analysis March 7, 2016

Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy March 7, 2016

MCAM and LAMA4 are highly enriched in tumor blood vessels of renal cell carcinoma and predict patient outcome March 4, 2016

Germline genetic variations in PDZD2 and ITPR2 genes are associated with clear cell renal cell carcinoma in Chinese population March 4, 2016

A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy March 4, 2016

Reexamining the association between positive surgical margins and survival after partial nephrectomy in a large American cohort March 4, 2016

Prognostic role of urinary collecting system invasion in renal cell carcinoma: a systematic review and meta-analysis March 4, 2016

Surgical Management of Local Recurrences of Renal Cell Carcinoma March 4, 2016

Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy March 4, 2016

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy March 4, 2016

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study March 3, 2016

Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations March 3, 2016

Page 292 of 457